Literature DB >> 26539962

Macrophages dictate the progression and manifestation of hypertensive heart disease.

David Kain1, Uri Amit1, Chana Yagil2, Natalie Landa1, Nili Naftali-Shani1, Natali Molotski1, Vered Aviv3, Micha S Feinberg4, Orly Goitein5, Tammar Kushnir5, Eli Konen5, Fredrik H Epstein6, Yoram Yagil2, Jonathan Leor7.   

Abstract

BACKGROUND: Inflammation has been implicated in the initiation, progression and manifestation of hypertensive heart disease. We sought to determine the role of monocytes/macrophages in hypertension and pressure overload induced left ventricular (LV) remodeling. METHODS AND
RESULTS: We used two models of LV hypertrophy (LVH). First, to induce hypertension and LVH, we fed Sabra salt-sensitive rats with a high-salt diet. The number of macrophages increased in the hypertensive hearts, peaking at 10 weeks after a high-salt diet. Surprisingly, macrophage depletion, by IV clodronate (CL) liposomes, inhibited the development of hypertension. Moreover, macrophage depletion reduced LVH by 17% (p<0.05), and reduced cardiac fibrosis by 75%, compared with controls (p=0.001). Second, to determine the role of macrophages in the development and progression of LVH, independent of high-salt diet, we depleted macrophages in mice subjected to transverse aortic constriction and pressure overload. Significantly, macrophage depletion, for 3 weeks, attenuated LVH: a 12% decrease in diastolic and 20% in systolic wall thickness (p<0.05), and a 13% in LV mass (p=0.04), compared with controls. Additionally, macrophage depletion reduced cardiac fibrosis by 80% (p=0.006). Finally, macrophage depletion down-regulated the expression of genes associated with cardiac remodeling and fibrosis: transforming growth factor beta-1 (by 80%) collagen type III alpha-1 (by 71%) and atrial natriuretic factor (by 86%).
CONCLUSIONS: Macrophages mediate the development of hypertension, LVH, adverse cardiac remodeling, and fibrosis. Macrophages, therefore, should be considered as a therapeutic target to reduce the adverse consequences of hypertensive heart disease.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Fibrosis; Heart; Hypertension; Hypertrophy; Macrophage; Remodeling

Mesh:

Year:  2015        PMID: 26539962     DOI: 10.1016/j.ijcard.2015.10.126

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  19 in total

1.  Oral NaHCO3 Activates a Splenic Anti-Inflammatory Pathway: Evidence That Cholinergic Signals Are Transmitted via Mesothelial Cells.

Authors:  Sarah C Ray; Babak Baban; Matthew A Tucker; Alec J Seaton; Kyu Chul Chang; Elinor C Mannon; Jingping Sun; Bansari Patel; Katie Wilson; Jacqueline B Musall; Hiram Ocasio; Debra Irsik; Jessica A Filosa; Jennifer C Sullivan; Brendan Marshall; Ryan A Harris; Paul M O'Connor
Journal:  J Immunol       Date:  2018-04-16       Impact factor: 5.422

Review 2.  The Extracellular Matrix in Ischemic and Nonischemic Heart Failure.

Authors:  Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2019-06-20       Impact factor: 17.367

3.  Chronic Benzene Exposure Aggravates Pressure Overload-Induced Cardiac Dysfunction.

Authors:  Igor N Zelko; Sujith Dassanayaka; Marina V Malovichko; Caitlin M Howard; Lauren F Garrett; Shizuka Uchida; Kenneth R Brittian; Daniel J Conklin; Steven P Jones; Sanjay Srivastava
Journal:  Toxicol Sci       Date:  2021-12-28       Impact factor: 4.849

4.  Recombinant EGFL7 Mitigated Pressure Overload-Induced Cardiac Remodeling by Blocking PI3K γ /AKT/ NFκB Signaling in Macrophages.

Authors:  Lei Li; Ying Zhao; Ying Hu; Xiaohui Wang; Qun Jin; Ying Zhao
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

Review 5.  Role of Inflammation in Heart Failure.

Authors:  Lily F Shirazi; Joe Bissett; Francesco Romeo; Jawahar L Mehta
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

Review 6.  Critical roles of macrophages in pressure overload-induced cardiac remodeling.

Authors:  Dan Yang; Han-Qing Liu; Fang-Yuan Liu; Nan Tang; Zhen Guo; Shu-Qing Ma; Peng An; Ming-Yu Wang; Hai-Ming Wu; Zheng Yang; Di Fan; Qi-Zhu Tang
Journal:  J Mol Med (Berl)       Date:  2020-10-31       Impact factor: 4.599

Review 7.  CARD9 as a potential target in cardiovascular disease.

Authors:  Matthew R Peterson; Samantha E Haller; Jun Ren; Sreejayan Nair; Guanglong He
Journal:  Drug Des Devel Ther       Date:  2016-11-22       Impact factor: 4.162

Review 8.  Immunity and Hypertension.

Authors:  Rong M Zhang; Kyle P McNerney; Amy E Riek; Carlos Bernal-Mizrachi
Journal:  Acta Physiol (Oxf)       Date:  2020-06-25       Impact factor: 6.311

9.  Tetrahydrobiopterin Protects Against Hypertrophic Heart Disease Independent of Myocardial Nitric Oxide Synthase Coupling.

Authors:  Toru Hashimoto; Vidhya Sivakumaran; Ricardo Carnicer; Guangshuo Zhu; Virginia S Hahn; Djahida Bedja; Alice Recalde; Drew Duglan; Keith M Channon; Barbara Casadei; David A Kass
Journal:  J Am Heart Assoc       Date:  2016-03-21       Impact factor: 5.501

Review 10.  The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC.

Authors:  Stefan Frantz; Ines Falcao-Pires; Jean-Luc Balligand; Johann Bauersachs; Dirk Brutsaert; Michele Ciccarelli; Dana Dawson; Leon J de Windt; Mauro Giacca; Nazha Hamdani; Denise Hilfiker-Kleiner; Emilio Hirsch; Adelino Leite-Moreira; Manuel Mayr; Thomas Thum; Carlo G Tocchetti; Jolanda van der Velden; Gilda Varricchi; Stephane Heymans
Journal:  Eur J Heart Fail       Date:  2018-01-15       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.